Ageing with HIV: a multidisciplinary review

1.

Centers for Disease Control–CDC (USA). AIDS among persons aged > or = 50 years—United States, 1991–1996. MMWR Morb Mortal Wkly Rep. 1998;47:21–7.

2.

Brothers TD, Rockwood K. Biologic aging, frailty, and age-related disease in chronic HIV infection. Curr Opin HIV AIDS. 2014;9:412–8.PubMedCrossRef

3.

Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci. 2014;69:833–42.PubMedCentralPubMedCrossRef

4.

Thomas DR. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr. 2007;26:389–99.PubMedCrossRef

5.

McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, Aldrovandi GM, Cardoso SW, Santana JL, Brown TT. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937–46.PubMedCentralPubMedCrossRef

6.

Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14:877–82.PubMedCrossRef

7.

Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52:1061–8.PubMedCrossRef

8.

Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS. 2014;9:294–301.PubMedCrossRef

9.

Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, Margolick JB. Multicenter AIDS Cohort Study. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62:1279–86.PubMedCrossRef

10.

Detels R, Jacobson L, Margolick J, Martinez-Maza O, Muñoz A, Phair J, Rinaldo C, Wolinsky S. The multicenter AIDS Cohort Study, 1983 to …. Public Health. 2012;126:196–8.PubMedCentralPubMedCrossRef

11.

Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, Goulet J, Simberkoff M, Butt AA, Rimland D, Rodriguez-Barradas MC, Gibert CL, Oursler KA, Brown S, Leaf DA, Goetz MB, Bryant K. Veterans Aging Cohort Study (VACS): overview and description. Med Care. 2006;44:S13–24.PubMedCentralPubMedCrossRef

12.

Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, Rimland D, Rodriguez-Barradas MC, Tate J, Yin MT, Justice AC. Veterans Aging Cohort Study Project Team. Physiologic frailty and fragility fracture in HIV infected male veterans. Clin Infect Dis. 2013;56:1498–504.PubMedCentralPubMedCrossRef

13.

Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect. 2009;59:346–52.PubMedCrossRef

14.

Piggott DA, Muzaale AD, Mehta SH, Brown TT, Patel KV, Leng SX, Kirk GD. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One. 2013;8:e54910.PubMedCentralPubMedCrossRef

15.

Althoff KN, Jacobson LP, Cranston RD, Detels R, Phair JP, Li X, Margolick JB, Multicenter ACS. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci. 2014;69:189–98.PubMedCrossRef

16.

Erlandson KM, Allshouse AA, Jankowski CM, Duong S, Mawhinney S, Kohrt WM, Campbell TB. Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy. HIV Clin Trials. 2012;13:324–34.PubMedCentralPubMedCrossRef

17.

Ianas V, Berg E, Mohler MJ, Wendel C, Klotz SA. Antiretroviral therapy protects against frailty in HIV-1 infection. J Int Assoc Provid AIDS Care. 2013;12:62–6. doi:10.1177/1545109712457241.PubMedCrossRef

18.

Terzian AS, Holman S, Nathwani N, Robison E, Weber K, Young M, Greenblatt RM, Gange SJ. Women’s Interagency HIV Study. Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of ART. J Womens Health (Larchmt). 2009;18:1965–74.CrossRef

19.

Pathai S, Gilbert C, Weiss HA, Cook C, Wood R, Bekker LG, Lawn SD. Frailty in HIV-infected adults in South Africa. J Acquir Immune Defic Syndr. 2013;62:43–51.PubMedCentralPubMedCrossRef

20.

Adeyemi O, Livak B. Higher Veterans Aging Cohort Study (VACS) index scores in HIV-positive adults with CD4 counts <200 cells/mm3 despite viral suppression. J Acquir Immune Defic Syndr. 2013;63:e78–81.PubMedCrossRef

21.

Onen NF, Overton ET. A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging. Curr Aging Sci. 2011;4:33–41.PubMedCrossRef

22.

Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, Wilson CC, MaWhinney S, Kohrt WM, Campbell TB. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. JID. 2013;208:249–59.PubMedCentralPubMedCrossRef

23.

Rickbaugh TM, Kilpatrick RD, Hultin LE, Hultin PM, Hausner MA, Sugar CA, Althoff KN, Margolick JB, Rinaldo CR, Detels R, Phair J, Effros RB, Jamienson BD. The dual impact oh HIV-1 infection and aging on naïve CD4 + T-cells: additive and distinct patterns of impairment. PLoS One. 2011;6:e16459.CrossRef

24.

Viard JP, Macroft A, Chiesi A, Kirk O, Røge B, Panos G, Vetter N, Bruun JN, Johnson M, Lundgren JD. EuroSIDA Study Group. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183:1290–4.PubMedCrossRef

25.

Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, Napolitano LA, Douek DC, Mbisa G, Deeks S, Harris JM, Barbour JD, Gross BH, Francis IR, Halvorsen R, Asaad R, Lederman MM. Poor CD4 cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001;15:1749–56.PubMedCrossRef

26.

Alcaide ML, Parmigiani A, Pallikkuth S, Roach M, Freguja R, Della Negra M, Bolivar H, Fischi MA, Pahwa S. Immune activation in HIV-infected aging women on antiretrovirals-Implication for age-associated comorbidities: a cross-sectional pilot study. PLoS One. 2013;8:e63804.PubMedCentralPubMedCrossRef

27.

Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R. Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011;53:1130–9.PubMedCrossRef

28.

Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6.PubMedCrossRef

29.

Kendall CE, Wong J, Taljaard M, Glazier RH, Hogg W, Younger J, Manuel DG. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;13:161. doi:10.1186/1471-2458-14-161.CrossRef

30.

De Socio GV, Ricci E, Parruti G, Maggi P, Madeddu G, Quirino T, Bonfanti P. Chronological and biological age in HIV infection. J Infect. 2010;61:428–30.PubMedCrossRef

31.

De Socio GV, Ricci E, Maggi P, Parruti G, Pucci G, Di Biagio A, Calza L, Orofino G, Carenzi L, Cecchini E, Madeddu G, Quirino T, Schillaci G. CISAI Study Group. Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. Am J Hypertens. 2014;27:222–8.PubMedCrossRef

32.

Satlin MJ, Hoover DR, Glesby MJ. Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS. 2011;25:5–12.PubMedCentralPubMedCrossRef

33.

Madeddu G, Fois AG, Calia GM, Babudieri S, Soddu V, Becciu F, Fiori ML, Spada V, Lovigu C, Mannazzu M, Caddeo A, Piras B, Pirina P, Mura MS. Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era? Infection. 2013;41:347–53.PubMedCrossRef

34.

Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV Infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614–22.PubMedCrossRef

35.

Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, Abbara S, Ribaudo H, Douglas PS, Hoffmann U, Lo J, Grinspoon SK. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014;28:2061–70.PubMedCentralPubMedCrossRef

36.

Nadkarni GN, Konstantinidis I, Wyatt CM. HIV and the aging kidney. Curr Opin HIV AIDS. 2014;9:340–5.PubMedCrossRef

37.

Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, di Gregorio S, Puig J, Gómez G, Clotet B, Negredo E. Osteoporosis Study Group High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010;24:2827–33.PubMedCrossRef

38.

Onen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K. Tebas P Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11:100–9.PubMedCrossRef

39.

Castronuovo D, Cacopardo B, Pinzone MR. Bone disease in the setting of HIV infection:update and review of the literature. Eur Rev Med Pharmacol Sci. 2013;17:2413–9.PubMed

40.

Shiau ST, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals. AIDS. 2013;27:1949–57.PubMedCentralPubMedCrossRef

41.

Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclasto-genesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481–8.PubMedCentralPubMedCrossRef

42.

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963–72.PubMedCrossRef

43.

Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52–8.PubMedCrossRef

44.

Kearney F, Moore AR, Donegan CF, Lambert J. The ageing of HIV: implications for geriatric medicine. Age Ageing. 2010;39:536–41.PubMedCrossRef

45.

Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte AD, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41.PubMedCrossRef

46.

Warriner AH, Burkholder GA, Overton ET. HIV-related metabolic comorbidities in the current ART era. Infect Dis Clin N Am. 2014;28:457–76.CrossRef

47.

McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67:699–714.PubMed

48.

Valcour VG. HIV, aging, and cognition: emerging issues. Top Antivir Med. 2013;21:119–23.PubMed

49.

Ciccarelli N, Fabbiani M, Grima P, Falasca K, Tana M, Baldonero E, Colafigli M, Silveri MC, Vecchiet J, Cauda R, Di Giambenedetto S. Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients. Infection. 2013;41:1103–9.PubMedCrossRef

50.

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group, HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3–16.PubMedCentralPubMedCrossRef

51.

Calcagno A, Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S, Lipani F, Raviolo S, Di Perri G, Bonora S. Prevalence and predictors of blood-brain barrier damage in the HAART era. J Neurovirol. 2014;20:521–5. doi:10.1007/s13365-014-0266-2 Epub 2014 Jun 28.PubMedCrossRef

52.

Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med. 2011;19:137–42.PubMedPubMedCentral

53.

Marquine MJ, Umlauf A, Rooney AS, Fazeli PL, Gouaux BD, Paul Woods S, Letendre SL, Ellis RJ, Grant I, Moore DJ, HIV Neurobehavioral Research Program (HNRP) Group. The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr. 2014;65:190–7.PubMedCentralPubMedCrossRef

54.

Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression–a systematic review of interventions. Psychol Health Med. 2011;16:493–527.PubMedCrossRef

55.

Albini L, Calabresi A, Gotti D, Ferraresi A, Festa A, Donato F, Magoni M, Castelli F, Quiros-Roldan E. Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. AIDS Res Hum Retroviruses. 2013;29:1097–104.PubMedCrossRef

56.

Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Gerstoft J, Obel N. Causes of death among Danish HIV patients compared with population controls in the period 1995–2008. Infection. 2012;40:627–34.PubMedCrossRef

57.

Ehren K, Hertenstein C, Kümmerle T, Vehreschild JJ, Fischer J, Gillor D, Wyen C, Lehmann C, Cornely OA, Jung N, Gravemann S, Platten M, Wasmuth JC, Rockstroh JK, Boesecke C, Schwarze-Zander C, Fätkenheuer G. Causes of death in HIV-infected patients from the Cologne-Bonn cohort. Infection. 2014;42:135–40.PubMedCrossRef

58.

Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94.PubMedCrossRef

59.

Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153:452–6.PubMedCentralPubMedCrossRef

60.

Brooks JT, Buchacz K, Gebo KA, Mermin J. HIV infection and older Americans. Am J Public Health. 2012;102:1516–26.PubMedCentralPubMedCrossRef

61.

Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015:1–18 (Epub ahead of print). PubMed PMID: 25600059.

62.

Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;1:2079–86.

63.

Holtzman C, Armon C, Tedaldi E, Chmiel JS, Buchacz K, Wood K, Brooks JT, The HOPS Investigators. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013;28:1302–10.PubMedCentralPubMedCrossRef

64.

Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L, Swiss HIV, Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66:2107–11.PubMedCrossRef

65.

Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67–76.PubMedCrossRef

66.

McLachlan AJ, Pont LG. Drug metabolism in older people–a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci. 2012;67:175–80.PubMedCrossRef

67.

Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24:1519–27.PubMedCentralPubMedCrossRef

68.

Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B. Renal impairment in patients receiving a tenofovir-ART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2013;62:375–80.PubMedCrossRef

69.

Calcagno A, de Gonzalez Requena D, Simiele M, D’Avolio A, Tettoni MC, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. Antimicrob Agents Chemother. 2013;57:1840–3.PubMedCentralPubMedCrossRef

70.

Kakuda TN, Wade JR, Snoeck E, Vis P, Schöller-Gyüre M, Peeters MP, Corbett C, Nijs S, Vingerhoets J, Leopold L, De Smedt G, Woodfall BJ, Hoetelmans RM. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients. Clin Pharmacol Ther. 2010;88:695–703.PubMedCrossRef

71.

Crawford KW, Spritzler J, Kalayjian RC, Parsons T, Landay A, Pollard R, Stocker V, Lederman MM, Flexner C, AIDS Clinical Trials Protocol 5015 Team. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses. 2010;26:635–43.PubMedCentralPubMedCrossRef

72.

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C, UK Collaborative HIV Cohort Study. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013;68:1354–9.PubMed

73.

Cattaneo D, Baldelli S, Cerea M, Landonio S, Meraviglia P, Simioni E, Cozzi V, Fucile S, Gazzaniga A, Clementi E, Galli M, Rizzardini G, Gervasoni C. Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing. Antimicrob Agents Chemother. 2012;56:6132–6.PubMedCentralPubMedCrossRef

74.

Croteau D, Letendre S, Best B, Clifford D, Gelman B, Marra C, McArthur J, McCutchan JA, Simpson D, Grant I. Older age is associated with higher ARV concentrations in CSF in HIV + individuals. 19th conference on retroviruses and opportunistic infections. 2012. Seattle (abstract 592).

75.

Gervasoni C, Meraviglia P, Landonio S, Riva A, Galli M, Rizzardini G, Cattaneo D. Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women. J Antimicrob Chemother. 2013;68:1206–7.PubMedCrossRef

76.

Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, Kashuba AD. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet. 2012;51:809–22.PubMedCentralPubMedCrossRef

77.

Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505. doi:10.1086/655681.PubMedCrossRef

78.

Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, Honda H, Tanuma J, Yazaki H, Tsukada K, Honda M, Teruya K, Kikuchi Y, Oka S. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6:e22661.PubMedCentralPubMedCrossRef

79.

Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 2009;23:1971–5.PubMedCentralPubMedCrossRef

80.

El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. Strategies for Management of Antiretroviral Therapy (SMART) Study Group CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.PubMedCrossRef

81.

Tripathi A, Liese AD, Winniford MD, Jerrell JM, Albrecht H, Rizvi AA, Zhang J, Duffus WA. Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014;37:517–22.PubMedCrossRef

82.

Sabin C, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D’Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–26.PubMedCrossRef

83.

Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, Pedersen C, Gerstoft J, Sørensen HT. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Medicine. 2010;11:130–6.PubMedCrossRef

84.

Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–24.CrossRef

85.

Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Hou N, Owens DK, Desai M. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8:e59551.PubMedCentralPubMedCrossRef

86.

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individuals antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228–38.PubMedCrossRef

87.

Bedimo R, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53:84–91.PubMedCrossRef

88.

Brothers C, Hernandez J, Cutrell A, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20–8.PubMedCrossRef

89.

Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25:1993–2004.PubMedCrossRef

90.

Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, Marcus KA. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acuqir Immune Defic Syndr. 2012;61:441–7.CrossRef

91.

Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, Baker D, Woolley I, Emery S, STEAL study group. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS. 2010;24:2657–63.PubMedCrossRef

92.

Martınez E, Larrousse M, Podzamczer D, Perez I, Gutierrez F, Lonca´ M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM, BICOMBO Study Team. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS. 2010;24:F1–9.PubMedCrossRef

93.

Jong E, Meijers JC, van Gorp EC, Spek CA, Mulder JW. Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther. 2010;16:7–9.

94.

Baum PD, Sullam PM, Stoddart CA, McCune JM. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS. 2011;25:2243–8.PubMedCentralPubMedCrossRef

95.

Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther. 2014;19:141–7.PubMedPubMedCentralCrossRef

96.

US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: http://www.aidsinfo.nih.gov.ezp-prod1.hul.harvard.edu/ContentFiles. Accessed October 2014.

97.

Marcotullio S, Andreoni M, Antinori A, d’Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A, Rapporteur Committee, Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. New Microbiol. 2012;35:259–77.PubMed

98.

Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, Tian M, Fredrick L, Podsadecki T, Norton M, Nilius A. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses. 2013;29:256–65.PubMed

99.

Nozza S, Galli L, Antinori A, Chiappetta S, Mazzotta F, Zaccarelli M, Ottou S, De Battista D, Pogliaghi M, Di Pietro M, Malnati M, Ripa M, Bonora S, Lazzarin A. VEMAN Study Group. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. Clin Microbiol Infect. 2014. doi:10.1016/j.cmi.2014.12.006 pii: S1198-743X(14)00142-6.

100.

Calcagno A, Nozza S, de Gonzalez Requena D, Galli A, D’Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. J Antimicrob Chemother. 2013;68:1686–8.PubMedCrossRef

101.

Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet. 2013;381:2091–9.PubMedCrossRef

102.

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, on behalf NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–51. doi:10.1016/S0140-6736(14)61170-3.PubMedCrossRef

103.

Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A, NEAT001/ANRS143 Study Group. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942–51.PubMedCrossRef

104.

Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, Benetucci J, Mancini M, Yang R, Wirtz V, Percival L, Zhang J, Zhu L, Arikan D, Farajallah A, Nguyen BY, Leavitt R, McGrath D, Lataillade M, The Spartan Study Team. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012;13:119–30.PubMedCrossRef

105.

Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S, SPARE study team. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One. 2013;8:e73639.PubMedCentralPubMedCrossRef

106.

Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D’Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother. 2013;68:1364–72.PubMedCrossRef

107.

Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients. Antivir Ther. 2014;19:117–23.PubMedCrossRef

108.

Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao J, Teppler H, Dinubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P, STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807–16.PubMedCrossRef

109.

Landovitz RJ, Ribaudo HJ, Ofotokun I, Wang H, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, Lennox JL for the A5257 Study Team. Efficacy and tolerability of atazanvir, raltegravir, or darunavir with FTC/Tenofovir: ACTG 5257. 21st Conference on retroviruses and opportunistic infections. 2014 (abstract #85).

110.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S, SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week, results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735–43.PubMedCrossRef

111.

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18.PubMedCrossRef

112.

Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S, ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–3.PubMedCrossRef

113.

Curtis G, Nichols C, Stainsby J, Lim, Aylott A, Wynne B, Clark A, Bloch M, Maechler G, Martin-Carpenter L, Raffi F, Min S. Dolutegravir: clinical and laboratory safety in integrase inhibitor–naive patients. HIV Clin Trials. 2014;15:199–208.PubMedCrossRef

114.

Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-boosted Darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;. doi:10.1007/s40261-014-0266-2.PubMedCentralPubMed

115.

Theou O, Stathokostas L, Roland KP, Jakobi JM, Patterson C, Vandervoort AA, Jones GR. The effectiveness of exer-cise interventions for the management of frailty: a systematic review. J Aging Res. 2011;2011:569194.PubMedCentralPubMedCrossRef

116.

Gill TM, Baker DI, Gottschalk M, Peduzzi PN, Allore H, Byers A. A program to prevent functional decline in physically frail, elderly persons who live at home. N Engl J Med. 2002;347:1068–74.PubMedCrossRef

117.

Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, Roberts SB, Kehayias JJ, Lipsitz LA, Evans WJ. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med. 1994;330:1769–75.PubMedCrossRef

118.

Forster A, Lambley R, Hardy J, Young J, Smith J, Green J, Burns E. Rehabilitation for older people in long-term care. Cochrane Database Syst Rev. 2009;1 (CD004294).

119.

Longo V, Bonato M, Bossolasco S, Laura Galli, Andrea Caumo, Gaspare Pavei, Adriano Lazzarin, Giampiero Merati, Antonio LaTorre, Paola Cinque. Brisk walking improves inflammatory markers in ART-treated patients. CROI. 2104 (abstract 763).

120.

Lin AL, Coman D, Jiang L, Rothman DL, Hyder F. Caloric restriction impedes age-related decline of mitochondrial function and neuronal activity. J Cereb Blood Flow Metab. 2014;34:1440–3.PubMedCentralPubMedCrossRef

121.

Farazi M, Nguyen J, Goldufsky J, Linnane S, Lukaesko L, Weinberg AD, Ruby CE. Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunol Immunother. 2014;63:615–26.PubMedCentralPubMedCrossRef

122.

Soare A, Weiss EP, Pozzilli P. Benefits of caloric restriction for cardiometabolic health, including type 2 diabetes mellitus risk. Diabetes Metab Res Rev. 2014;30:41–7.PubMedCrossRef

123.

Rizza W, Veronese N, Fontana L. What are the roles of calorie restriction and diet quality in promoting healthy longevity? Ageing Res Rev. 2014;13:38–45.PubMedCrossRef

124.

Fontana L, Partridge L, Longo VD. Extending healthy lifespan—from yeast to humans. Science. 2010;328:321–6.PubMedCentralPubMedCrossRef

125.

Lorenzini A. How much should we weigh for a long and healthy life span? the need to reconcile caloric restriction versus longevity with body mass index versus mortality data. Front Endocrinol (Lausanne). 2014;30:121.

126.

Sohal RS, Forster MJ. Caloric restriction and the aging process: a critique. Free Radic Biol Med. 2014;73:366–82.PubMedCrossRef

127.

Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D’Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD. The ketone metabolite -hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015 (Epub ahead of print).

128.

Brothers TD, Kirkland S, Guaraldi G, Falutz J, Theou O, Johnston BL, Rockwood K. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis. 2014;210:1170–9. doi:10.1093/infdis/jiu258.PubMedCrossRef

129.

Leenders M, van Loon LJ. Leucine as a pharmaconutrient to prevent and treat sarcopenia and type 2 diabetes. Nutr Rev. 2011;69:675–89.PubMedCrossRef

130.

Qin LQ, Xun P, Bujnowski D, Daviglus ML, Van HL, Stamler J, He K. Higher branched-chain amino acid intake is associated with a lower prevalence of being overweight or obese in middle aged East Asian and western adults. J Nutr. 2011;141:249–54.PubMedCentralPubMedCrossRef

131.

Cavuoto P, Fenech MF. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev. 2012;38:726–36.PubMedCrossRef

132.

McPherson RA, Hardy G. Clinical and nutritional benefits of cysteine-enriched protein supplements. Curr Opin Clin Nutr Metab Care. 2011;14:562–8.PubMedCrossRef

133.

Ripps H, Shen W. Review taurine: a ‘‘very essential’’ amino acid. Mol Vis. 2012;18:2673–86.PubMedCentralPubMed

134.

Gualano B, Roschel H, Lancha-Jr AH, Brightbill CE, Rawson ES. In sickness and in health: the widespread application of creatine supplementation. Amino Acids. 2012;43:519–29.PubMedCrossRef

135.

Bollhalder L, Pfeil AM, TomonagaY Schwenkglenks M. A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation. Clin Nutr. 2013;32:213–23.PubMedCrossRef

136.

Kitamura A, Tsurugizawa T, Uematsu A, Torii K, Uneyama H. New therapeutic strategy for amino acid medicine: effects of dietary glutamate on gut and brain function. J Pharmacol Sci. 2012;118:138–44.PubMedCrossRef

137.

Jonker R, Engelen MP, Deutz NE. Role of specific dietary amino acids in clinical conditions. Br J Nutr. 2012;108:S139–48.PubMedPubMedCentralCrossRef

138.

Smith RL, de Boer R, Brul S, Budovskaya Y, van Spek H. Premature and accelerated aging: HIV or HAART? Front Genet. 2013;28:328.

139.

Biagi E, Candela M, Turroni S, Garagnani P, Franceschi C, Brigidi P. Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol Res. 2013;69:11–20.PubMedCrossRef

140.

Klatt NR, Canary LA, Sun X, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013;123:903–7.PubMedCentralPubMed

141.

Ortiz AM, Klase ZA, Carmack KM, et al. Probiotic and IL-21 treatment promotes Th17 cell recovery in ARV-treatment of pigtail macaques. CROI. 2014 (abstract 83).

142.

Gori A, Rizzardini G, Van Land B, et al. Specific probiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults. Results of the ‘COPA’ pilot randomized trial. Mucosal Immunol. 2011;4:554–63.PubMedCentralPubMedCrossRef

143.

Wilson NL, Moneyham LD, Alexandrov AW. A systematic review of probiotics as a potential intervention to restore gut health in HIV infection. J Assoc Nurses AIDS Care. 2013;24:98–111.PubMedCrossRef

144.

Gonzalez-Hernandez LA, Jave-Suarez LF, Fafutis-Morris M, et al. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial. Nutr J. 2012;11:90.PubMedCentralPubMedCrossRef

145.

Stiksrud B, Nowak P, Kvale D, et al. Decreased levels of D-Dimer after probiotic supplementation in patients receiving ART. CROI. 2014 (abstract 342).

146.

Overton E, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56:1471–9.PubMedCentralPubMedCrossRef

147.

Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, et al. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One. 2013;8:e52828.PubMedCentralPubMedCrossRef

148.

Funderburg N, Jiang Y, Debanne S, Storer N, Labbato D, Clagett B, Robinson J, Lederman M, McComsey G, McComsey G. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin infect Dis. 2014;58:588–9.PubMedCentralPubMedCrossRef

149.

Eckard AR, Jiang Y, Debanne S, Funderburg N, McComsey G. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209:1156–64.PubMedCentralPubMedCrossRef

150.

Longenecker CT, Hileman Co Storer NJ, et al. Rosuvastatin lowers cystatin c in HIV-infected subjects on antiretroviral therapy. SATURN-HIV (abstract 743).

151.

Skaaby T, Husemoen LL, Pisinger C, Jorgensen T, Thuesen BH, Fenger M, et al. Vitamin D status and cause-specific mortality: a general population study. PLoS One. 2012;7:e52423.PubMedCentralPubMedCrossRef

152.

Schottker B, Ball D, Gellert C, Brenner H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev. 2013;12:708–18.PubMedCrossRef

153.

Shardell M, Hicks GE, Miller RR, Kritchevsky S, Andersen D, Bandinelli S, Cherubini A, Ferrucci L. Association of low vitamin D levels with the frailty syndrome in men and women. J Gerontol A Biol Sci Med Sci. 2009;64:69–75.PubMedCrossRef

154.

Escota GV, Cross S, Powderly WG. Vitamin D and calcium abnormalities in the HIV-infected population. Endocrinol Metab Clin North Am. 2014;43:743–67.PubMedCrossRef

155.

Eckard AR, McComsey GA. Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals. Curr HIV/AIDS Rep. 2014;11:263–70.PubMedCentralPubMedCrossRef

156.

Havers F, Smeaton L, Gupte N, Detrick B, Bollinger RC, Hakim J, Kumarasamy N, Andrade A, Christian P, Lama JR, Campbell TB, Gupta A, ACTG PEARLS, NWCS 319 Study Teams. 25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. J Infect Dis. 2014;210:244–53.PubMedCentralPubMedCrossRef

157.

Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP, EuroSIDA in EuroCOORD. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis. 2014;210:234–43.PubMedCrossRef

158.

Piconi S, Parisotto S, Rizzardini G, Passerini P, Terzi R, Argenteri B, Meraviglia P, Capetti A, Biasin M, Trabattoni D, Clerici M. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy–treated immunologic nonresponders. Blood. 2011;118:3263–72.PubMedCrossRef

159.

Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M, Aandahl EM, Sandset PM, Taskén K, Kvale D. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol. 2011;85:6557–66.PubMedCentralPubMedCrossRef

160.

Carcelain G, Autran B. Immune interventions in HIV infection. Immunol Rev. 2013;254:355–71.PubMedCrossRef

161.

Sereti I, Estes JD, Thompson WL, Morcock, Fischl MA, Croughs T, Beq S, de Lafaye Micheaux S, Yao MD, Ober A, Wilson EM, Natarajan V, Imamichi H, Boulassel MR, Lederman MM, Routy JP. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10:e1003890.PubMedCentralPubMedCrossRef

162.

Cimbro R, Vassena L, Arthos J, Cicala C, Kehrl JH, Park C, Sereti I, Lederman MM, Fauci AS, Lusso P. IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa. Blood. 2012;120:2610–9.PubMedCentralPubMedCrossRef

163.

Schuetz A, Phuang-Ngern Y, Rerknimitr R, et al. Early ART initiation prevents disruption of the mucosal barrier and subsequent T-Cell activation. CROI. 2014 (abstract 77).

164.

Massanella M, Llibre JM, Marfil S, et al. Effect of Raltegravir intensification in the cytokine profile of treated HIV + individuals. CROI. 2014 (abstract 300).

165.

Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D’Amore C, Baldelli F, Fiorucci S. Efficacy of the CCR5 antagonist maraviroc in reducing early Ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation. 2013;127:2114–24.PubMedCrossRef

166.

Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4 + T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203:1474–83.PubMedCentralPubMedCrossRef

167.

Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP, Vriesema A, Georgiou NA, Garssen J, Clerici M, Lange JM, (BTE) Blinded Nutritional Study for Immunity and Tolerance Evaluation Study Team. The immunomodulatory nutritional intervention NR100157 reduced CD4 + T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study). Clin Infect Dis. 2013;57:139–46.PubMedCrossRef

168.

Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V. Mayer L Selective regulation of cytokine by hydroxychloroquine: inhibition of interleukin-1 alpha (IL-1 alpha) and IL-6 in human monocytes and T cells. J Rheumatol. 1993;20:803–8.PubMed

169.

Routy JP, Angel J, Patel M, Kanagaratham C, Radzioch D, Kema I, Gilmore N, Ancuta P, Singer J, Jenabian MA. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2015;16:48–56.PubMedCrossRef

170.

Shan L, Siliciano RF. Unraveling the relationship between microbial translocation and systemic immune activation in HIV infection. J Clin Invest. 2014;124:2368–71.PubMedCentralPubMedCrossRef

171.

Kristoff J, Haret-Richter G, Ma D, Ribeiro RM, Xu C, Cornell E, Stock JL, He T, Mobley AD, Ross S, Trichel A, Wilson C, Tracy R, Landay A, Apetrei C, Pandrea I. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest. 2014;124:2802–6.PubMedCentralPubMedCrossRef

172.

Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT, AIDS Clinical Trials Group A5296 Team. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014;210:1549–54.PubMedPubMedCentralCrossRef

173.

Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, McLaughlin B, Landay AL, Adeyemi O, LE Gilman, Clagett B, Rodriguez B, Martin JN, Schacker TW, Shacklett BL, Palmer S, Lederman MM, Deeks SG. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4 + T-cell recovery: a randomized trial. Blood. 2013;121:4635–46.PubMedCentralPubMedCrossRef

174.

Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y, Amarnath S, Fowler DH, Radwan M, Young MT, Pittman K, Kubes P, Agarwal HK, Parang K, Hinton DR, Bastos-Carvalho A, Li S, Yasuma T, Mizutani T, Yasuma R, Wright C, Ambati J. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science. 2014;346:1000–3.PubMedCentralPubMedCrossRef

Springer Medizin

Ageing with HIV: a multidisciplinary review

Abstract

Introduction

Material and methods

Conclusion and discussion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Update Innere Medizin

Springer Medizin

Abstract

Introduction

Material and methods

Conclusion and discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Rapid reduction of viruria and stabilization of allograft function by fusidic acid in a renal transplant recipient with JC virus-associated nephropathy

A novel case of Raoultella planticola urinary tract infection in a female: comment on ‘Nosocomial pneumonia caused by carbapenem-resistant Raoultella planticola: a case report and literature review’

Prevalence of intestinal parasite infections and associated clinical symptoms among patients with end-stage renal disease undergoing hemodialysis

Rational application of adenosine deaminase activity in cerebrospinal fluid for the diagnosis of tuberculous meningitis

On the search for novel treatment modalities for HIV-associated intestinal barrier dysfunction